TORONTO, ON / ACCESSWIRE / March 17, 2017 / ACME Resources Inc. (TSXV: ACY.H) (the “Company”) wishes to announce an amendment to a proposed non-brokered private-placement offering of Company equity.

The private placement will comprise an offering of 3,000,000 common shares at a price of $CDN 0.05 per share (the “Offering”) for gross proceeds of up to $CDN 150,000. This Offering amends the original proposed private placement that was announced on October 4, 2016.

The proceeds received from the Offering will be used for general working capital purposes while the Company continues to explore options with regard to a Qualifying Transaction of the Company, as such term is defined in Policy 2.4 of the TSX Venture Exchange.

All securities issued in connection with the financing will be subject to a statutory four month plus one day hold period. The Offering is subject to regulatory approval.

ACME Resources Corp. trades with symbol ACY.H on the NEX Tier of the TSX Venture Exchange and currently has 4,101,950 shares outstanding (4,349,118 fully diluted). Trading of the shares of the Company are currently halted.

For further information contact:

Paul Ankcorn – Chief Executive Officer
Telephone: (416) 866-2200

Cautionary Note Regarding Forward-looking Statements

Certain information in this press release may contain forward-looking statements. Such statements are based on the current expectations of the management of the Company. Trading in the securities of the Company should be considered highly speculative. Except as required by applicable securities laws, forward looking statements speak only as of the date on which they are made and, unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: ACME Resources Inc.

ReleaseID: 457558

LOS ANGELES, CA / ACCESSWIRE / March 17, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against (“OneMain” or the “Company”) (NYSE: OMF). Investors, who purchased or otherwise acquired OneMain shares between March 3, 2015, and November 7, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

OneMain develops, markets, and sells financial products through its subsidiaries. On November 7, 2016, OneMain announced unsatisfactory third quarter financial results. When this information was revealed to the investing public, the value of OneMain stock fell nearly 40%, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 457561

PLEASANT HILL, CA / ACCESSWIRE / March 17, 2017 / Textmunication Holdings, Inc. (OTC PINK: TXHD), a cloud-based mobile SMS marketing platform provider, is minority-owner of Aspire Consulting Group LLC (“Aspire”). On January 5, 2016, Textmunication Holdings, Inc. (“Textmunication”) entered into a Share Exchange Agreement with Aspire Consulting Group, LLC (“Aspire”). Aspire is a verified Service Disabled Veteran-Owned Small Business (SDVOSB).

Pursuant to the terms of the Exchange Agreement, Textmunication acquired 49% of all of the issued and outstanding membership units of Aspire. As a result of the Share Exchange Agreement, Textmunication became a minority owner of Aspire.

Aspire Consulting Group & SDVOSB:

Aspire is headquartered in the business hub of Washington, D.C. and provides IT consulting and solution-based services to commercial, state, and federal agencies. Aspire is connected to the government procurement community and has advisors who have served in state government cabinet positions and Fortune 500 companies. This network, along with the SDVOSB certification, positions Aspire as a sought after partner for government contracts.

There are less than 6,000 verified SDVOSB firms in the Unites States. Aspire is verified through the Center for Verification and Evaluation (CVE) program within the Veterans Affairs Department. Aspire’s acceptance into the “Veterans First Contracting Program” is critical. The purpose is to ensure legitimately owned and controlled VOSBs and SDVOSBs are able to compete for VA VOSB and SDVOSB set-aside contracts and are credited by VA’s large prime contractors for subcontract plan achievements.

Aspire Milestones:

Aspire was notified, on March 1, 2017, that it was awarded a significant 10-year government contract. Aspire is a strategic teammate on the CMS SPARC Indefinite Delivery/Indefinite Quantity (IDIQ) contracting vehicle. The ceiling on the IDIQ is $25B and is shared with multiple companies. The Prime requested Aspire join the team based on its healthcare past performance and powerful SDVOSB certification. Aspire successfully performed on a 2016 Cloud and Big Data healthcare project gaining critical past performance marks. The Aspire leadership team has substantial Health IT (HIT) experience and is connected to the HIT network in D.C.

The remaining teammates come from Fortune 500 companies and well-known Federal System Integrators. Strategic teaming is key to winning the numerous task orders delivered under this long-term IDIQ vehicle. The Aspire SPARC team is divided into specialty areas and set-aside certifications. The SPARC agreement offers substantial revenue opportunity for Aspire. Once task orders within the IDIQ are won, announcements and revenue guidance will be made. Task order revenues vary in size, but most are substantial and are multi-year arrangements split amongst the teammates.

There are strict SDVOSB work share mandates required by the U.S. government. The Veterans Benefit Act of 2003 requires each government agency to set aside at least 3% of contracts for SDVOSBs. On the state level, the percentages vary, but in most cases are higher. Aspire is competing for state contracts where the SDVOSB requirement is a minimum 7% of total revenue.

The SPARC agreement also provides Aspire the necessary past performance credentials to compete long-term and be successful with future contracting proposals. Past performance is a critical benchmark, in addition to procurement set-aside certifications. Aspire’s SDVOSB certification is one of the most coveted in government contracting. The CMS SPARC contract is one of the largest IDIQs in government and carries substantial past performance metrics.

Aspire just submitted a proposal for the Veterans Affairs (VA) VECTOR SDVOSB contract. This is a $25B IDIQ centered on Management, Analysis, Training, Outreach, Supply Chain and Human Resource staffing. Aspire’s team on VECTOR now awaits the award of this contract. Two other contracts are pending. One is for system modernization of a state’s Motor Vehicle Administration (MVA) infrastructure. The other as a subcontractor on a key federal agency.

Aspire has teaming agreements with Northrop Grumman – the #2 federal systems integrator, Tech Mahindra – one of the largest business transformation firms in the world and a Direct hiring agreement with Phase One Consulting Group on its Department of Transportation (DOT) and Commodity Futures Trading Commission (CFTC) programs. The SDVOSB certification helps these companies hit specific government goals as it relates to veteran-owned business credits.

Aspire – Textmunication Partnership:

Textmunication acquired a minority-stake in Aspire gaining government contracting access. The partnership also allows Aspire’s management team to open new SMS verticals in the government sector. Aspire is building-out a government contracting operation for the long-term.

The combination of government contracting access and new SMS opportunities makes the synergy strong. Textmunication will update the investment community once additional Aspire awards and task orders are won.

Text TXHD to shortcode 87365 to sign-up for news alerts and announcements via SMS.

About Textmunication Holdings, Inc.

Textmunication is an online mobile marketing platform service provider that helps health clubs, martial arts studios, salons, and healthcare firms communicate with their members by allowing them to build loyalty, engage member retention, and create new business through a non-intrusive, value added medium. Textmunication connects members to the content they desire through any mobile device for health clubs and salon events, as well as promotions. Clients can send the most up-to-date offers, discounts, member alerts, events, PT schedules, or any other personalized campaign (www.textmunication.com).

Text DEMO to shortcode 87365 to sign up for a demonstration on our SMS solution.

Safe Harbor Provision:

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this press release as they reflect Textmunication Holdings’ current expectations with respect to future events and are subject to risks and uncertainties that may cause actual results to differ materially from those contemplated. Potential risks and uncertainties include, but are not limited to, the risks described in Textmunication Holdings’ filings with the Securities and Exchange Commission. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and any document referred to in this press release.

Contact:

Wais Asefi
Textmunication
(800) 677-7003
wais@textmunication.com

SOURCE: Textmunication Holdings, Inc.

ReleaseID: 457496

NEW YORK, NY / ACCESSWIRE / March 17, 2017 /
Array Biopharma and Corcept Therapeutics are two companies whose stock prices both fell on Thursday, following the trend of the general market. Both stocks are trading near the $10 per share level with similar market cap range, but the insider and institutional investor activity can be described as different as night and day. During the week, both stocks showed similar price movement patterns. Current stockholders and potential buyers both can learn from the price movements as they relate to each company’s internal activity.

RDI Initiates
Coverage:

Array Biopharma Inc. https://ub.rdinvesting.com/news/?ticker=ARRY

Corcept Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CORT

Array Biopharma is a biotech company whose main focus is on developing proprietary drugs for the treatment of cancer and inflammatory diseases. The stock traded down 17 cents on Thursday to $10.74 a share. It recently has had a number of institutional investors buying more stock over the last 6 months. Most recently, Putnam Investments LLC raised its stake in Array, buying more than 90,922 shares of stock and Bogle Investment Management increased their holding in the company in February. Mild interest in the company by institutional investors in 2016 spiked dramatically in the 4th quarter, with buyers outnumbering sellers by almost a 3 to 1 margin. The last 5 days saw the stock has risen as high as $11.50 a share, but settled back towards its current price the end of the week. Array’s investment ratings has changed by number of investment research firms in last couple of months, with upgrade from “hold” to “buy” by Zacks, “buy” ratings given by Piper Jaffray and Leerink Swann in January, whereas JP Morgan chase has cut rating to “neutral” in February, Whereas Vetr Inc has recently upgraded stock from “strong sell” to “sell”. Company has made a loss of $0.14 per share on revenue of $44.5 million for the second quarter of fiscal 2017 which is better than consensus call for loss of $0.18 a share, according to Thomson Reuters.

Access RDI’s Array Biopharma Research Report at: https://ub.rdinvesting.com/news/?ticker=ARRY

Corcept Therapeutics saw its stock drop 30 cents a share at the beginning of Thursday’s trading session and struggled to recover. It lost almost 3 percent of its value nearing the end of the day. The company accounted that an SEC filing by Director Patrick G. Enright revealed he sold 600,000 shares of Corcept stock on Wednesday, March 15th leaving him with just over 200,000 shares invested in the company. The sale sliced Mr. Enright’s commitment by 75 percent. This sale follows a late 2016 surge of insider sales that saw more than $50 million leave the firm in the last two quarters of 2016. The last 5 trading days shows a high of $11.22 on Monday, then moving down as the weekend approached. The company has mixed of “sell” and “buy” ratings, with Piper Jaffray recently reiterated “overweight” rating on the stock. Concert has reported loss of $2.28 a share for year 2016 against earnings of $1.09 a share reported in year 2015.

Access RDI’s Corcept Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CORT

Our Actionable Research on Array Biopharma Inc. (NASDAQ: ARRY) and Corcept Therapeutics Inc. (NASDAQ: CORT) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457536

NEW YORK, NY / ACCESSWIRE / March 17, 2017 / There has been significant interest in both companies by investment rating firms and individual investors over the past quarter. The interest is not necessarily reflective of the stocks trading volume, as the ratings have changed to indicate there is a positive trend, but that the price may be near topping out for the short term, causing investors to wait for further financials.

RDI Initiates
Coverage:

Amicus Therapeutics,
Inc. https://ub.rdinvesting.com/news/?ticker=FOLD

Sarepta Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=SRPT

Amicus stock started the Thursday trading day with positive gain, rising to $7.28 a share, then fell back and was on a downward trend by the end of the day, down 24 cents to $6.95, then had a late day rally to close at $7.12 cutting its day losses in half. The stock drop came in part from a general decline in the market, yet Zacks Investment Research upgraded is recommendation from “sell” to “hold.” Amicus has had a number of investment firms, including JP Morgan Chase, confirming or raising their rating of the company from a “hold” to a “buy” during the early months of 2017, with consensus rating as “outperform”. The company specializes in the development of treatments for patients with rare diseases. Its current lead candidate for Fabry disease is that the company hopes to be able to treat with its enzyme replacement therapy drug., migalastat HCl. Migalastat HCI is already approved in Europe under the trade name “Galafold” and has generated nearly $5 million of sales in the year 2016 mainly from its launch in Germany and the company hopes to launch it in US by 2020 and its competitors are “Relagel” of Shire and “Fabrazyme” of Sanofi, with the later having US FDA approval. For the Current quarter, Amicus has launched “Galafold” in U.K. and Italy. Another candidate currently in FDA Phase 2 stage is SD-101, topical treatment with the potential of first-to-market therapy to treat the rare and genetic disorder with skin blistering and lesions, Epidermolysis Bullosa (“EB”). Amicus has reported a net loss of $200 million or $1.49 a share for year 2016 as compared to net loss of $132.1 million or $1.20 a share reported in year 2015, and has started generating revenue from third quarter of 2016 with total of $5 million revenue for year 2016.

Access RDI’s Amicus Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=FOLD

On Thursday, Sarepta’s closing price of $31.63 $30.35 was nearly 6 percent lower than its Monday opening of $32.21 per share. The company’s rating has recently raised by Vetr Inc. from “buy” to “strong buy.” Oppenheimer Holdings reiterated its “outperform” rating on February 28th. Number of “buy” recommendations currently outweighs the “sell” by a 11 to 1 ratio. Sarepta has reported a net loss of $88.5 million or $1.62 a share for the year 2016 as compared to $64.7 million or $1.44 a share loss reported for the year 2015, mainly due to $40 million of upfront payment regarding licence agreement to Summit Therapeutics. Sarepta has started generating revenue from the end of third quarter of 2016 with net revenue of $5.4 million for the year 2016 from the shipments of EXONDYS 51. Cash, Cash equivalents and short term investment is standing at $329.3 million as of December 31, 2016 and during the current quarter Sarepta has agreed to sale priority review voucher for $125 million. There appears to be more upside to the stock based on the recommendations and future prospect, but Thursday’s close seems to be a setback.

Access RDI’s Sarepta Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=SRPT

Our Actionable Research on Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457535

DUBAI, UAE / ACCESSWIRE / March 17, 2017 / A general theme for 2017 has been clean and renewable energy. Traditional fossil fuels are making a major shift. Forbes recently wrote about the clean energy revolution saying, “Driven by its emissions-reduction potential, electricity consumption will grow twice as much as total energy demand, which is forecast to rise by up to 70% in the next 25 years according to the International Energy Agency (IEA).”

When it Began

The push towards cleaner energy began in 2016 when multiple countries agreed to make a major shift toward reducing greenhouse gas emissions. The oil rich middle east has historically viewed energy resources as a public good. However, over time countries throughout the middle east, including Yemen has proven that a lot of money is being dished out to these energy services.

A 2016 article published by the World Economic Forum highlighted the efforts of 196 countries limiting global temperatures.

“Countries in the Middle East and North Africa region are willing to do their share to mitigate climate change, as demonstrated by their respective Intended Nationally Determined Contributions. Morocco for one, indicated its interest to increase the share of renewables to 52 % by 2030, which is remarkable given the recent dependency on fossil fuels for power generation. It is clear that energy exporters are interested to maintain their role of global energy supplier, and have a stake in the global shift towards sustainable energy.”

Recent Efforts

More recently at the World Economic Forum in Davos, Switzerland, there were many conversations around the push towards green efforts.

Saudi Arabia is already “leaving” oil behind. “As far as oil prices, and oil, I have left that behind,” said Saudi oil minister Ali al-Naimi, who led the country’s oil sector for 21 years.

“Now, I’m much more interested in solar energy, making solar panels,” he added.

Speaking on January 20th at the World Economic Fo­rum in Davos, Switzerland, Saudi Energy Minister Khaled al Falih suggested that Saudi Arabia could become a “major exporter” of re­newable energy, saying, “solar that is produced in Saudi Arabia can be exported all the way to Europe through a network.”

What it means for Yemen

Crude oil, coffee, dried and salted fish, and liquefied natural gas were Yemen’s main exports in 2014. Flash forward to now and the country has ultimately halted exports. Solar, wind and thermal energy are all cheap options that could vastly help Yemen.

Affordable and clean energy is one of the 17 goals for the United Nations Development Programme. “Between 1990 and 2010, the number of people with access to electricity has increased by 1.7 billion, and as the global population continues to rise so will the demand for cheap energy.”

The clean energy revolution is a good thing for Yemen. For countries like Yemen, it is very important that energy sources are diversified. The UNDP says, “Decentralized energy systems can help limit the risks to the energy sector, such as those related to disasters.”

Clean energy in Yemen could reduce poverty, help with social progress and economic growth.

1 in 5 people around the globe are without electricity. Pushing towards greener resources can vastly help make energy accessible for all.

Haitham Alaini is an entrepreneur from Yemen with over 20 years of experience. He focuses on issues surrounding the environment, education, and preserving Yemen. Alaini is passionate about exploring innovative technology that will help improve Yemen, his native country.

To learn more about Haitham Alaini visit:

Haitham Alaini – Website: haithamalaini.org

Haitham Alaini (@haitham_alaini) – Twitter: https://twitter.com/haitham_alaini

Haitham Alaini – Facebook: https://www.facebook.com/haithammalaini?fref=ts

SOURCE: Haitham Alaini

ReleaseID: 457473

NEW YORK, NY / ACCESSWIRE / March 17, 2017 /
Federal Reserve Chairperson Janet Yellen has made it clear that she expects to recommend (a minimum) of three increases in the Federal Reserve interest rate in 2017. The extent of the effects of these rate hikes will depend in part on the size of the rate increase. For investors holding bank stocks, the question looms whether the hikes will positively impact the bank’s stock price. The key piece of financial data investors should look for is net interest position with respect to yield curve movement, Net interest margin what is left over from the profits after the banks pay off their loans, however bank’s derivatives hedging positions and trading portfolio positions also plays very significant role in affecting bank’s bottom line. On March 15th, the Fed voted 9 to 1 to start raising the rates by 25 basis points to the range between 0.75 percent and 1 percent. Here are two stocks, Bank of America and Citigroup, whose value will be directly affected by the expected increases.

RDI Initiates
Coverage:

Bank of America Corp. https://ub.rdinvesting.com/news/?ticker=BAC

Citigroup Inc. https://ub.rdinvesting.com/news/?ticker=C

Bank of America Corp. stock went up 4 5 cents a share to close at $25.22 per share. After hours trading has the stock up another 20 cents. There are differing opinions on the effect the interest rate hikes will have on the company. An RBC study listed 20 banks that could benefit from a rate hike, and Bank of America was among them. Using each bank’s assumption for the net interest revenue increase resulting from a 100 or 200 basis point increase in interest rates, we calculate that the top 20 banks would on average see an increase in net interest revenue equivalent to 7.1% of 2017 “estimated earnings”, they said. The company has it’s consensus rating stands at “overweight”, some investment analysts however are recommending to hold on to the bank stock as long as possible until the date of the rate hike can be seen on the horizon. The company had no initial response to the decision by the Federal Reserve or on its future operating profits. Bank has witnessed improved environment for credit changes and has generated significant higher trading revenue in the last quarter. On February 15, bank has reported 1.60 percent of credit card delinquency rate for January month versus 1.56 percent for the same on December.

Access RDI’s Bank of America Research Report at: https://ub.rdinvesting.com/news/?ticker=BAC

Citigroup is another major bank whose stock is certain to be impacted by the rate hike. Its stock jumped 32 cents a share to close at $61.15. Citigroup’s Chief Financial Officer John Gerspach said that while the company’s acquisition of CostCo’s portfolio from American Express has resulted in some financial benefit, the 2nd quarter of 2017 should a marked increase in revenues however it is yet to hit the bank’s bottom line. The news also included that Citigroup was chosen as one of three banks to work with Saudi Arabia’s as it prepares to help the country for an Islamic bond sale. The Saudi sale is a step towards helping the country manage its current budget deficit. Although effect of hike in interest rate on Citi’s profitability is still not clear, the other news gets better for the Citigroup, and investors may expect a sunny and warm financial summer given its fast start to 2017.

Access RDI’s Citigroup Research Report at: https://ub.rdinvesting.com/news/?ticker=C

Our Actionable Research on Bank of America Corp. (NYSE: BAC) and Citigroup Inc. (NYSE: C) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457542

NEW YORK, NY / ACCESSWIRE / March 17, 2017 /
Cara Therapeutics and GW Pharmaceuticals are biotech sectors stocks that have been on the rise but now are seeing their stock value changed by both the market and investment ratings firms. Many investors cling to their broker’s recommendations, while others always have one foot out the door. Looking at the stock prices of these companies over the last 30 days and taking into consideration their specific niche specialty may have you wondering the stocks are taking a breather from an upward trend or are headed south for a while.

RDI Initiates
Coverage:

Cara Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CARA

GW Pharmaceuticals
PLC https://ub.rdinvesting.com/news/?ticker=GWPH

Cara Therapeutics is a biopharmaceutical company that develops remedies for pain, with its primary focus on a person’s peripheral nervous system. The stock closed on Thursday at $15.65 a share, up 7 cents. It was not able to recover from the loss of its early morning price of $16.43. It reached its 2017 high price on March 3rd when it closed at $18.04. Recent investment ratings have moved the stock to a “buy” candidate, setting a price objective of between $20 and $22 on the high end. The optimism has funneled over to a few ratings firms that listed it as a “sell” stock. Likewise, some hedge funds have reduced their positions in Cara, while others, including Wells Fargo Bank, MN, have added to their positions. Cara has reported ($0.81) earnings per share (EPS) for the fourth quarter of 2016, missing the Zacks’ consensus estimate of ($0.48) by $0.33.

Access RDI’s Cara Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CARA

Some see GW Pharmaceuticals as one of the more interesting and risky companies on the NASDAQ and in the market in general. The company was created to focused on the development and sale of its therapeutics created from its proprietary cannabinoid product platform. Cannabinoids are found in cannabis, the most potent form being THC, and have a direct effect on the brain’s neurotransmitter cells. The stock closed on Thursday with a price of $122.97, down 98 cents from the previous day close. The stock hit a 90 day high on February 15th, closing at $132.51. But the industry itself is open to regulatory problems from the Federal government and a limited number of sales channels. The company currently only has one drug approved for sale, Sativex. Many investment firms shy away from making recommendations, yet the recommendations that are made tend to be “buy” or “hold” signals with 1 “sell” rating. GW pharmaceutical has reported a loss of GBP 15.6 million on revenue of GBP 2.06 million for the first quarter of fiscal 2017, as compared to reported loss of GBP 17.7 million on revenue of GBP 3.7 million for the same quarter prior year.

Access RDI’s GW Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=GWPH

Our Actionable Research on Cara Therapeutics Inc. (NASDAQ: CARA) and GW Pharmaceuticals PLC (NASDAQ: GWPH) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457538

NEW YORK, NY / ACCESSWIRE / March 17, 2017 /
Social media giant Facebook and up and comer Snap are two stocks that are likely to go in opposite directions if corporate marketers have anything to say about it. The current perception is that marketers prefer Instagram over Snap. Instagram is owned by – Facebook. Though this should not come as a surprise, the marketing reality has to be a major consideration for investors of Snap, who will likely have to rethink their positions.

RDI Initiates
Coverage:

Facebook Inc. https://ub.rdinvesting.com/news/?ticker=FB

Snap Inc. https://ub.rdinvesting.com/news/?ticker=SNAP

Facebook closed up 27 cents on Thursday, at $139.99 per share. For people outside of the investment world, the price of Facebook stock seems to be where it should be. But for the investing community, the company has seen a steady increase in price over the last 5 years. With nearly $405 billion in market capitalization, there is a surging sentiment that the stock may be over bought, as the stock has increased more than $100 per share since its initial offering, and added many investors along the way. Investor opinion varies, but supporters of the “buy” and “hold” positions maintain the company’s fundamentals are sound, and there is still plenty of room for upward movement. One very good piece of news for investors who got in on the initial offering is that it will take more than “a lot” to not realize a profit on Facebook stock as the company is reporting handsome growth in revenue year over year. During 2016, Facebook has generated $27.6 billion in revenue, 54 percent higher than the last year revenue and increased operating margin by 10 percent to 45 percent, while its earnings have more than doubled to $3.49 a share for the year from $1.29 a share reported in last year. For most investors, they can be patient and just ask the question, how much profit will I reel in.

Access RDI’s Facebook Research Report at: https://ub.rdinvesting.com/news/?ticker=FB

Snap started the day at $20.65 a share but fell 88 cents to close at $19.89. The stock was at $27.09 per share at the beginning of March but has since taken a slide to its current price. Today’s loss of more than 4 percent has left investors wondering if it can sustain the early interest of social media marketers and visitors. A recent study conducted with 1600 marketers by RBC Capital Markets and Ad Age arrived at the simple conclusion that marketers prefer Instagram to Snapchat. Inflicting an even deeper wound was that Snapchat was second to last in marketer preference, ahead of only AOL. However, social media is a huge market and there does not seem to be an end in sight to its use and growth. The question is whether Snap can find the right niche to fill and move forward to gain the confidence of their investors.

Access RDI’s Snap Research Report at: https://ub.rdinvesting.com/news/?ticker=SNAP

Our Actionable Research on Facebook Inc. (NASDAQ: FB) and Snap Inc. (NYSE: SNAP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457540

TORONTO, ON / ACCESSWIRE / March 17, 2017 / Xylitol Canada Inc. (TSX-V: XYL) (OTC PINK: XYLTF / XYLTD) (“Xylitol” or the “Corporation”) is pleased to announce that it has closed its acquisition of Nektar Naturals Holdings, Inc. (“Nektar”), as previously announced by press release on February 2, 2017 (the “Acquisition”). Pursuant to a share purchase agreement (the “Share Purchase Agreement”) entered into among the shareholders of Nektar and the Corporation, the Corporation acquired all of the issued and outstanding equity shares of Nektar in exchange for the issuance of 4,799,167 common shares of Xylitol (the “Purchase Price Shares”). Pursuant to the terms of the Share Purchase Agreement, Xylitol has agreed to service certain debt obligations in the aggregate principal amount of approximately US$598,000. The Corporation has also entered into an escrow agreement with the holders of the Purchase Price Shares and pursuant thereto 803,400 Purchase Price Shares have been deposited in escrow pending the outcome of certain debt obligations and a working capital adjustment post-closing.

“Our transaction with Nektar is a key milestone for Xylitol as we focus on product innovation to become a leading provider of natural sweetener products in the marketplace. Nektar brings key contributors to Xylitol, including national sales accounts such as Walmart, and a seasoned team of principals, including founder Jeremy B. Edelman and key shareholders,” said Steven Haasz, Chief Executive Officer of Xylitol.

“We are beyond excited to be merging with Xylitol. With our shared resources and complimentary product portfolios, we are on a trajectory toward amazing things. I take great pride in the people and their hard work that have made Nektar Naturals what it is today. We now turn our sights toward the future as we build a globally recognized brand of natural sweeteners,” said Jeremy B. Edelman.

Xylitol is also pleased to announce that it has closed a second tranche of its previously announced non-brokered private placement offering today resulting in the issuance by the Corporation of 2,808,333 common shares (the “Common Shares”) at a subscription price of $0.12 per share (post-Consolidation) for aggregate gross proceeds of CAD $337,000 (the “Offering”). The Common Shares issued pursuant to the Offering are subject to a four month hold period expiring July 17, 2017. The second tranche of the Offering was primarily subscribed for by a vendor in the Acquisition. In aggregate, between the first and second tranche of its non-brokered private placement, the Corporation has raised $2,087,000 in equity.

The Corporation intends to use the proceeds for general and working capital purposes.

A director of the Corporation subscribed for $40,000 worth of common shares in the Offering. Participation by a director in the Offering is considered to be a “related party transaction” as defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Offering is exempt from the formal valuation and minority shareholder approval requirements of Multilateral Instrument 61-101, as neither the fair market value of the securities being issued to insiders, nor the consideration being paid by such insiders, exceeds 25% of the Corporation’s market capitalization.

Xylitol is also pleased to welcome Julie Reid to its board of directors. Mrs. Reid has worked with the Corporation since 2004 and has focused on its sales and marketing efforts. The Board is looking forward to Mrs. Reid’s continued contributions. Mrs. Reid’s appointment remains subject to the approval of the TSX Venture Exchange.

In addition, the board of directors of Xylitol has approved a grant of an aggregate of 1,717,392 options (the “Options”) and 1,145,833 restricted share units (the “RSUs”) to certain directors and officers of the Corporation. 1,111,254 of the Options shall vest immediately, and 606,138 options shall vest as to 33% on each of the first, second, and third anniversaries of the grant date. Each Option shall be exercisable for one common shares of the Corporation at an exercise price of $0.12 per share. The RSUs shall vest immediately and have a deemed issuance price of $0.12 per share.

About Xylitol Canada Inc.

Xylitol Canada is a consumer packaged goods business focused on an assortment of natural sweetener based products, including xylitol, coconut palm sugar, and honey. The Corporation operates a 30,000 square foot facility in Colorado where it produces and packages a full catalog of natural sweetener products, most notably its natural sweetener alternatives. Xylitol Canada services major retail customers such as Loblaws, Whole Foods, Costco, Trader Joe’s, Sprouts, and distributors, including UNFI and KeHE.

For more information about Xylitol, please contact:

Steven Haasz
CEO and a director of Xylitol Canada Inc.
416.288.1019
shaasz@xylitolcanada.com

Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Xylitol Canada Inc.

ReleaseID: 457556